Inflammatory myofibroblastic tumor. 18F-FDG PET/CT findings

Silván, A. Díaz; Riera, A. Allende; García, D. Cabello; Hernández, O. Vilahomat; Gimeno, Eva Martínez

doi:10.1016/j.remnie.2018.06.007

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biological behaviors of IMT and CD are typically benign or tend to exhibit benign traits, featuring imaging characteristics akin to those of benign tumors, often presenting spherical soft tissue shadows with clear boundaries. The maximum standard uptake value of these tumors in PET/CT imaging is significantly lower compared to that of GISTs ( 22 – 24 ). Lymphoma, characterized by relatively uniform mass density and unclear boundaries with the adjacent gastrointestinal wall, is rarely necrotic and is often accompanied by multiple lymph node enlargements in the small and large curvatures of the stomach, abdominal trunk, or mesentery.…”

Section: Discussionmentioning

confidence: 83%

Case report: detection of multiple sporadic gastrointestinal stromal tumors by dual-time 18 F-FDG PET/CT

Li,

Shang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors affecting the gastrointestinal tract. Typically, GISTs are solitary; however, in rare cases, they may be multiple and appear in one or more organs. Multiple GISTs can appear in familial GISTs, children, or certain tumor syndromes such as neurofibromatosis type 1, Carney syndrome, and Carney-Stratakis syndrome. However, the diagnosis of primary multiple sporadic GISTs is often more difficult than that of these diseases. Herein, we report a case of multiple primary sporadic GISTs in a 64-year-old man, affecting the abdominal cavity and retroperitoneum, as identified through dual-time point positron emission tomography (PET) with 18F-labeled fluoro-2-deoxyglucose (18F-FDG) and computed tomography (18F-FDG PET/CT). Notably, the dual-time-point PET/CT revealed the migration of masses near the lower abdomen into the abdominal cavity. Furthermore, a significant increase in radioactive uptake of the mass 3 h after 18F-FDG injection compared with that 1 h after injection may be an important cue for its diagnosis.

show abstract

Section: Discussionmentioning

confidence: 83%

Case report: detection of multiple sporadic gastrointestinal stromal tumors by dual-time 18 F-FDG PET/CT

Li,

Shang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…A study involving 5 patients revealed a heterogeneous standardized uptake value (SUVmax) of approximately 10.9, with this value being predominantly influenced by tumor cellularity, nuclear atypia, and a relatively high proliferative index [59]. However, SUVmax values for IMT vary significantly, ranging from 1.84 to 28.6, depending on the specific case [76][77][78]. The utility of this diagnostic tool extends to the detection of metastatic disease and the monitoring of response to treatment [79].…”

Section: Diagnosismentioning

confidence: 99%

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

CHMIEL,

SłOWIKOWSKA,

BANASZEK

et al. 2024

View full text Add to dashboard Cite

Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.

show abstract

Inflammatory myofibroblastic tumor. 18F-FDG PET/CT findings

Cited by 2 publications

References 3 publications

Case report: detection of multiple sporadic gastrointestinal stromal tumors by dual-time 18 F-FDG PET/CT

Case report: detection of multiple sporadic gastrointestinal stromal tumors by dual-time 18 F-FDG PET/CT

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

Contact Info

Product

Resources

About